Skip to main content

Advertisement

SpringerLink
Log in

Gonadotropin releasing hormone antagonists and cryopreservation outcome: a review

  • Review Article
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Review

The outcome of freeze-thaw cycles with pronuclear stage oocytes or embryos, derived from collecting cycles stimulated with gonadotropin-releasing hormone (GnRH)-antagonists’ protocols, was reviewed.

Conclusion

The viability of cryopreserved pronuclear stage oocytes and embryos, the quality of transferred embryos and the pregnancy rates of the freeze-thaw cycles seem to be satisfactory regardless of the type and dose of GnRH-antagonist.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Albano C, Smitz J, Camus M, Riethmüller-Winzen H, Van Steirteghem AC, Devroey P (1997) Comparison of different doses of gonadotrophin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 67:917–922

    Article  CAS  PubMed  Google Scholar 

  2. Albano C, Felberbaum RE, Smitz J, Riethmüller-Winzen H, Engel J, Diedrich K, Devroey P (2000) Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist Cetrorelix and the LHRH-agonist buserelin. Hum Reprod 15:526–531

    Article  CAS  PubMed  Google Scholar 

  3. Al-Inany H, Aboulghar M (2002) GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 17:874–885

    Article  CAS  PubMed  Google Scholar 

  4. Asimakopoulos B, Nikolettos N, Al-Hasani S (2002) Outcome of cryopreserved pronuclear oocytes obtained after ovarian stimulation with either HMG or recFSH and the GnRH-antagonist Cetrorelix. Reprod Biomed Online 5 [Suppl 1]:52–56

  5. Asimakopoulos B, Nikolettos N, Al-Hasani S, Diedrich K (2003) An evaluation of the multiple dose protocol of Cetrorelix in single ovary women. In Vivo 17:89–92

    CAS  PubMed  Google Scholar 

  6. Brus L, Lambalk CB, de Koning J, Helder MN, Janssens RMJ, Schoemaker J (1997) Specific gonadotrophin-releasing hormone analogue binding predominantly in human luteinized follicular aspirates and not in human pre-ovulatory follicles. Hum Reprod 12:769–773

    Article  CAS  PubMed  Google Scholar 

  7. Casañ EM, Raga F, Bonilla-Musoles F, Polan ML (2000) Human oviductal gonadotropin-releasing hormone: possible implications in fertilization, early embryonic development and implantation. J Clin Endocrinol Metab 85:1377–1381

    PubMed  Google Scholar 

  8. Das K, Stout D, Hensleigh HC, Tagatz GE, Phipps WR, Leung BS (1991) Direct positive effect of EGF on the cytoplasmic maturation of mouse and human oocytes. Fertil Steril 55:1000–1004

    CAS  PubMed  Google Scholar 

  9. Dekel N, Sherizly I (1985) Epidermal growth factor induces maturation of rat follicle-enclosed oocytes. Endocrinology 116:406–409

    CAS  PubMed  Google Scholar 

  10. Dekel N, Lewysohn O, Ayalon D, Hazum E (1988) Receptor for GnRH are present in rat oocytes. Endocrinology 123:1205–1207

    CAS  PubMed  Google Scholar 

  11. De la Fuente R, O’Brien JM, Eppig JJ (1999) EGF enhances preimplantation developmental competence of maturing mouse oocytes. Hum Reprod 14:3060–3068

    Article  PubMed  Google Scholar 

  12. Diedrich K, Felberbaum R (1998) New approaches to ovarian stimulation. Hum Reprod 13 [Suppl 3]:1–13

    Google Scholar 

  13. Diedrich K, Diedrich C, Santos E, Zoll C, Al-Hasani S, Reismann T, Krebs D, Klingmüller D (1994) Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 9:788–791

    CAS  PubMed  Google Scholar 

  14. Felberbaum RE, Diedrich K (1999) Ovarian stimulation for IVF/ICSI with gonadotrophins and GnRH analogues: agonist and antagonists. Hum Reprod 14 [Suppl 1]:207–221

    Google Scholar 

  15. Felberbaum R, Reissmann T, Küpker W, Al-Hasani S, Bauer O, Schill T, Zoll C, Diedrich C, Diedrich K (1996) Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages. J Assist Reprod Genet 13:216–222

    CAS  PubMed  Google Scholar 

  16. Ganirelix Dose-Finding Study Group (1998) A double-blind, randomized, dose finding study to assess the efficacy of the GnRH antagonist Ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 13:3023–3031

    Article  PubMed  Google Scholar 

  17. Gonzalez-Barcena D, Vadillo Buenfil M, Garcia Procel E, Guerra-Arguero L, Cardenas Cornejo I, Comaru-Schally AM, Schally AV (1994) Inhibition of luteinizing hormone, follicle-stimulating hormone and sex steroid levels in men and women with a potent antagonist analogue of luteinizing hormone-releasing hormone, Cetrorelix (SB-75). Eur J Endocrinol 131:286–292

    CAS  PubMed  Google Scholar 

  18. Gordon K (2001) Gonadotropin-releasing hormone antagonists. Implications for oocyte quality and uterine receptivity. Ann NY Acad Sci 943:49–54

    CAS  PubMed  Google Scholar 

  19. Goud PT, Goud AP, Qian C, Laverge H, Van der Elst J, De Sutter P, Dhont M (1998) In-vitro maturation of human germinal vesicle stage oocytes: role of cumulus cells and epidermal growth factor in the culture medium. Hum Reprod 13:1638–1644

    Article  CAS  PubMed  Google Scholar 

  20. Hernandez ER (2000) Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod 15:1211–1216

    Article  CAS  PubMed  Google Scholar 

  21. Hershkovitz E, Marbach M, Bosin E, Levy J, Roberts CT, LeRoith D Jr, Schally AV, Sharoni Y (1993) Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors. J Clin Endocrinol Metab 77:963–968

    CAS  PubMed  Google Scholar 

  22. Hsueh AJ, Jones PB (1981) Extrapituitary actions of gonadotrophin-releasing hormone. Endocr Rev 2:437–461

    CAS  PubMed  Google Scholar 

  23. Kang SK, Choi KC, Tai CJ (2001) Estradiol regulates gonadotropin-releasing hormone (GnRH) and its receptor gene expression and antagonizes the growth inhibitory effects of GnRH in human ovarian surface epithelial and ovarian cancer cells. Endocrinology 142:580–588

    CAS  PubMed  Google Scholar 

  24. Karten MJ, Rivier JE (1986) Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev 7:44–46

    CAS  PubMed  Google Scholar 

  25. Kleinman D, Roberts CT, LeRoith D, Schally AV, Levy J, Sharoni Y (1993) Regulation of endometrial cancer cell growth by insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75. Regul Pept 48:91–98

    Article  CAS  PubMed  Google Scholar 

  26. Klingmüller D, Schepke M, Enzweiler C, Bidlingmaier F (1993) Hormonal response to the new GnRH-antagonist Cetrorelix. Acta Endocrinol 128:15–18

    PubMed  Google Scholar 

  27. Kol S (2000) GnRH antagonists in ART: lower embryo implantation? Hum Reprod 15:1881–1882

    Article  CAS  PubMed  Google Scholar 

  28. Kol S, Lightman A, Hillensjo T, Devroey P, Fauser B, Tarlatzis B, Mannaerts B, Itskovitz-Eldor J (1999) High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Hum Reprod 14:2242–2244

    Article  CAS  PubMed  Google Scholar 

  29. Kolibianakis E, Bourgain C, Albano C, Osmanagaoglu K, Smitz J, Van Steirteghem A, Devroey P (2002) Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril 78:1025–1029

    Article  PubMed  Google Scholar 

  30. Latouche J, Crumeyrolle-Arias M, Jordan D, Kopp N, Augendre-Ferrante B, Cedard L, Haour F (1989) GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. Endocrinology 125:1739–1741

    CAS  PubMed  Google Scholar 

  31. Ludwig M, Felberbaum RE, Devroy P, Albano C, Riethmüller-Winzen H, Schüler A, Engel J, Diedrich K (2000) Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix in controlled ovarian stimulation for assisted reproduction. Arch Gynecol Obstet 264:29–32

    Article  CAS  PubMed  Google Scholar 

  32. Ludwig M, Katalinic A, Diedrich K (2001) Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet 265:175–182

    CAS  PubMed  Google Scholar 

  33. Mannaerts B, Gordon K (2000) GnRH antagonists do not activate the GnRH receptor. Hum Reprod 15:1882–1883

    Article  CAS  PubMed  Google Scholar 

  34. Minaretzis D, Jakubowski M, Mortola JF, Pavlou SN (1995) Gonadotrophin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. J Clin Endocrinol Metab 80:430–434

    CAS  PubMed  Google Scholar 

  35. Moretti RM, Marelli MM, Dondi D, Poletti A, Martini L, Motta M, Limouta P (1996) Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 81:3930–3937

    CAS  PubMed  Google Scholar 

  36. Murdoch WJ (1995) Immunolocalization of a GnRH receptor site in murine endometrium that mediates apoptosis. Cell Tissue Res 282:527–529

    Article  CAS  PubMed  Google Scholar 

  37. Nathwani PS, Kang SK, Cheng KW, Choi K-C, Leung PCK (2000) Regulation of gonadotropin-releasing hormone and its receptor gene expression by 17beta-estradiol in cultured human granulosa-luteal cells. Endocrinology 141:1754–1763

    CAS  PubMed  Google Scholar 

  38. Nikolettos N, Al-Hasani S, Felberbaum R, Demirel LC, Riethmüller-Winzen H, Reissmann T, Schöpper B, Sturm R, Diedrich K (2000) Comparison of cryopreservation outcome with human pronuclear stage oocytes obtained by the GnRH antagonist, Cetrorelix, and GnRH agonists. Eur J Obstet Gynecol Reprod Biol 93:91–95

    Article  CAS  PubMed  Google Scholar 

  39. Nikolettos N, Al-Hasani S, Felberbaum R, Demirel LC, Kupker W, Montzka P, Xia YX, Schöpper B, Sturm R, Diedrich K (2001) Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. Eur J Obstet Gynecol Reprod Biol 97:202–207

    Google Scholar 

  40. Nikolettos N, Asimakopoulos B, Diedrich K, Al-Hasani S (2004) Triptorelin versus Cetrorelix in intracytoplasmic sperm injection cycles in women with a single ovary. Eur J Obstet Gynecol Reprod Biol (in press)

  41. Olivennes F, Fanchin R, Bouchard P, de Ziegler D, Taieb J, Selva J, Frydman R (1994) The single or dual administration of the gonadotrophin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer programme. Fertil Steril 62:468–476

    CAS  PubMed  Google Scholar 

  42. Olivennes F, Fanchin R, Bouchard P, Taieb J, Selva J, Frydman R (1995) Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in vitro fertilization cycles: a pilot study. Hum Reprod 10:1382–1386

    CAS  PubMed  Google Scholar 

  43. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, Nicollet B, Zorn JR, Bouchard P, Frydman R (2000) Prospective, randomized, controlled study of in-vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LHRH) antagonist (Cetrorelix) or a depot formula of an LH-RH agonist (Triptoreline). Fertil Steril 73:314–320

    Article  CAS  PubMed  Google Scholar 

  44. Ortmann O, Diedrich K (1999) Pituitary and extrapituitary actions of gonadotrophin-releasing hormone and its analogues. Hum Reprod 14 [Suppl 1]:194–206

    Google Scholar 

  45. Ortmann O, Weiss JM, Diedrich K (2001) Embryo implantation and GnRH antagonists. Ovarian actions of GnRH antagonists. Hum Reprod 16:608–611

    Article  CAS  PubMed  Google Scholar 

  46. Pinski J, Reile H, Halmos G, Groot K, Schally AV (1994) Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent dunning R-3327-AT-1 rat prostate cancer. Int J Cancer 59:51–55

    CAS  PubMed  Google Scholar 

  47. Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, Schally AV (1995) Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod 10:1974–1981

    PubMed  Google Scholar 

  48. Sadler SE (1991) Type III phosphodiesterase plays a necessary role in the growth-promoting actions of insulin, IGF-I and Ha p21ras in Xenopus laevis oocytes. Mol Endocrinol 5:1939–1946

    CAS  PubMed  Google Scholar 

  49. Seelig AS, Al-Hasani S, Katalinic A, Schöpper B, Sturm R, Diedrich K, Ludwig M (2002) Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle. Fertil Steril 77:472–475

    Article  PubMed  Google Scholar 

  50. Shirahige Y, Cook CB, Pinski J et al (1994) Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice. Int J Oncol 5:3052–3060

    Google Scholar 

  51. Tarlatzis BC, Billi HN (2003) Gonadotropin-releasing hormone antagonists: impact of IVF practice and potential non-assisted reproductive technology applications. Curr Opin Obstet Gynecol 15:259–264

    Article  PubMed  Google Scholar 

  52. Tarlatzis BC, Kolibianakis EM (2002) Direct ovarian effects and safety aspects of GnRH agonists and antagonists. Reprod Biomed Online 5 [Suppl 1]:8–13

Download references

Author information

Authors and Affiliations

  1. Laboratory of Reproductive Physiology-IVF, Faculty of Medicine, Democritus University of Thrace, 68100, Dragana, Alexandroupolis, Greece

    N. Nikolettos, B. Asimakopoulos & M. Simopoulou

  2. Department of Obstetrics/Gynaecology, Medical University Lübeck, Ratzerburger Allee 160, 23538, Lübeck, Germany

    S. Al-Hasani & K. Diedrich

Authors
  1. N. Nikolettos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Asimakopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Simopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Al-Hasani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Diedrich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Nikolettos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nikolettos, N., Asimakopoulos, B., Simopoulou, M. et al. Gonadotropin releasing hormone antagonists and cryopreservation outcome: a review. Arch Gynecol Obstet 270, 69–73 (2004). https://doi.org/10.1007/s00404-003-0597-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-003-0597-3

Keywords

Search

Navigation